- Categories:About Us
- Time of issue:2019-05-24 00:00:00
IASO Biotherapeutics is an innovative, mechanism-driven, clinical stage biotechnology company based in China and the U.S. Focusing on discovering, developing, and manufacturing innovative medicines for cancer and autoimmune diseases. It is the mission of IASO Biotherapeutics to provide innovative and effective therapies to patients in China and around the world.
Founded in 2017, at IASO we are advancing our discovery pipeline, building a strong clinical development and operations team and developing our own GMP pilot and commercial manufacturing capabilities in Shanghai and Nanjing. And in support of these activities, we have established a business development branch in the US. In addition, we have developed a fully human antibody platform to provide high-quality antibody sequences for cell and antibody drugs. The company’s lead product, CT103A, a fully-human CAR T-cell therapy product targeting BCMA, has entered into a Phase II pivotal clinical trial. We have a diverse pipeline of more than ten novel therapeutics under development at various stages. This strong clinical development capacity fueled with internal innovative R&D business model will provide sustainable competitive advantages for IASO Biotherapeutics now and for the future.
Backed by prestigious investors such as HillHouse, our experienced team has secured partnerships with leading academia and global industry principals. IASO aims to become a trusted partner of choice for global biopharmaceutical companies seeking to advance our platform and assets in the China market and building long-term strategic relationships for global innovative first-in-class and best-in-class drug development.
IASO Biotherapeutics has rapidly expanded with several offices across China and the U.S. As of February 2021, the company has a global team of approximately 350 employees.